Targeted Therapies and Tailored Dosing: The New Era in ABMR Treatment

Chair: Jen Li (AU)

Is there still a role for anti IL-6R in ABMR treatment?

Roslyn B. Mannon (US)

Is anti-CD38 the most promising agent for ABMR?

Katharina Mayer (AT)

What does monitoring AUC add compared to C-trough only?

Teun van Gelder (NL)

Model Informed precision dosing

Anders Asberg (NO)